Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

在充满挑战的市场环境中，Alector Inc. (ALEC)股价触及52周新低，跌至2.61美元。这一显著下跌反映了该生物技术公司的整体趋势，过去一年其股价下跌了20.16%。投资者正密切关注Alector的表现，因为该公司正在经历一个充满波动和投资者谨慎的时期，希望公司的战略举措最终能够引导其重回增长和复苏的轨道。

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

【11 月 26 日，美国生物制药公司 Alector(ALEC.US)盘前跌超 33.5%，报 2.63 美元。】消息显示，Alector 公司的实验性药物在一项中期试验中未达减缓阿尔茨海默氏症进展的主要终点，将停止该药物的长期扩展研究。此外，该公司计划在 2023 年 12 月 31 日前裁员 17%，涉及 244 ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

11月26日｜美国生物制药公司Alector (ALEC.US) ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...